Targeting death receptors to fight cancer: From biological rational to clinical implementation

Current Medicinal Chemistry

Volumn 17, Issue 25, 2010, Pages 2713-2728

  Mocellin, S ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Anticancer therapy; Cancer; Death receptors; Tumor biology

Indexed keywords

ANTINEOPLASTIC AGENT; APOMAB; BORTEZOMIB; CISPLATIN; DEATH RECEPTOR; FAS LIGAND; FLUOROURACIL; GEMCITABINE; LEXTUMUMAB; MAPATUMUMAB; SORAFENIB; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CELL DEATH; CLINICAL TRIAL; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NONHUMAN; PROTEIN EXPRESSION; SOLID TUMOR; TUMOR RESISTANCE;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FAS LIGAND PROTEIN; HUMANS; MICE; MICE, TRANSGENIC; NEOPLASMS; RECEPTORS, DEATH DOMAIN; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77955593658     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710791859342     Document Type: Article

References (182)

1. Bridgham, J. T.; Wilder, J. A.; Hollocher, H.; Johnson, A. L. All in the family: evolutionary and functional relationships among death receptors. Cell Death Differ., 2003, 10, 19-25.
2. Ricci, M. S.; Zong, W. X. Chemotherapeutic approaches for targeting cell death pathways. Oncologist, 2006, 11, 342-357.
3. Cotter, T. G. Apoptosis and cancer: the genesis of a research field. Nat. Rev. Cancer, 2009, 9, 501-507.
4. Gerspach, J.; Wajant, H.; Pfizenmaier, K. Death ligands designed to kill: development and application of targeted cancer therapeutics based on proapoptotic TNF family ligands. Results Probl. Cell Differ., 2009, 49, 241-273.
5. Mahmood, Z.; Shukla, Y. Death receptors: Targets for cancer therapy. Exp. Cell Res., 2010, 316, 887-899.
6. Ashkenazi, A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev., 2008, 19, 325-331.
7. Takeda, K.; Stagg, J.; Yagita, H.; Okumura, K.; Smyth, M. J. Targeting death-inducing receptors in cancer therapy. Oncogene, 2007, 26, 3745-3757.
8. de Thonel, A.; Eriksson, J. E. Regulation of death receptors- relevance in cancer therapies. Toxicol. Appl. Pharmacol., 2005, 207, 123-132.
9. Ghobrial, I. M.; Witzig, T. E.; Adjei, A. A. Targeting apoptosis pathways in cancer therapy. CA Cancer J. Clin., 2005, 55, 178-194.
10. Hehlgans, T.; Pfeffer, K. The intriguing biology of the tumour necrosis factor/tumour necrosis factor receptor superfamily: players, rules and the games. Immunology, 2005, 115, 1-20.
11. Aggarwal, B. B. Signalling pathways of the TNF superfamily: a double-edged sword. Nat. Rev. Immunol., 2003, 3, 745-756.
12. Chen, G.; Goeddel, D. V. TNF-R1 signaling: a beautiful pathway. Science, 2002, 296, 1634-1635.
13. Pfeffer, K. Biological functions of tumor necrosis factor cytokines and their receptors. Cytokine Growth Factor Rev., 2003, 14, 185-191.
14. Ghosh, S.; Karin, M. Missing pieces in the NF-kappaB puzzle. Cell, 2002, 109 Suppl, S81-S96.
15. Li, X.; Yang, Y.; Ashwell, J. D. TNF-RII and c-IAP1 mediate ubiquitination and degradation of TRAF2. Nature, 2002, 416, 345-347.
16. Leist, M.; Jaattela, M. Four deaths and a funeral: from caspases to alternative mechanisms. Nat. Rev. Mol. Cell. Biol., 2001, 2, 589-598.
17. Locksley, R. M.; Killeen, N.; Lenardo, M. J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell, 2001, 104, 487-501.
18. Kim, J. W.; Choi, E. J.; Joe, C. O. Activation of death-inducing signaling complex (DISC) by pro-apoptotic C-terminal fragment of RIP. Oncogene, 2000, 19, 4491-4499.
19. Varfolomeev, E. E.; Ashkenazi, A. Tumor necrosis factor: an apoptosis JuNKie? Cell, 2004, 116, 491-497.
20. Orlowski, R. Z.; Baldwin, A. S., Jr. NF-kappaB as a therapeutic target in cancer. Trends Mol. Med., 2002, 8, 385-389.
21. Irmler, M.; Thome, M.; Hahne, M.; Schneider, P.; Hofmann, K.; Steiner, V.; Bodmer, J. L.; Schroter, M.; Burns, K.; Mattmann, C.; Rimoldi, D.; French, L. E.; Tschopp, J. Inhibition of death receptor signals by cellular FLIP. Nature, 1997, 388, 190-195.
22. Jaattela, M.; Benedict, M.; Tewari, M.; Shayman, J. A.; Dixit, V. M. Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. Oncogene, 1995, 10, 2297-2305.
23. Fulda, S.; Kufer, M. U.; Meyer, E.; van Valen, F.; Dockhorn-Dworniczak, B.; Debatin, K. M. Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene, 2001, 20, 5865-5877.
24. Aggarwal, B. B. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-kappaB. Ann. Rheum. Dis., 2000, 59 Suppl 1, i6-16.
25. Gulbins, E.; Grassme, H. Ceramide and cell death receptor clustering. Biochim. Biophys. Acta, 2002, 1585, 139-145.
26. De Nadai, C.; Sestili, P.; Cantoni, O.; Lievremont, J. P.; Sciorati, C.; Barsacchi, R.; Moncada, S.; Meldolesi, J.; Clementi, E. Nitric oxide inhibits tumor necrosis factor-alpha-induced apoptosis by reducing the generation of ceramide. Proc. Natl. Acad. Sci. U.S.A., 2000, 97, 5480-5485.
27. Liu, B.; Andrieu-Abadie, N.; Levade, T.; Zhang, P.; Obeid, L. M.; Hannun, Y. A. Glutathione regulation of neutral sphingomyelinase in tumor necrosis factor-alpha-induced cell death. J. Biol. Chem., 1998, 273, 11313-11320.
28. Fehrenbacher, N.; Gyrd-Hansen, M.; Poulsen, B.; Felbor, U.; Kallunki, T.; Boes, M.; Weber, E.; Leist, M.; Jaattela, M. Sensitization to the lysosomal cell death pathway upon immortalization and transformation. Cancer Res., 2004, 64, 5301-5310.
29. ten Hagen, T. L.; Seynhaeve, A. L.; Eggermont, A. M. Tumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed. Immunol. Rev., 2008, 222, 299-315.
30. Carswell, E. A.; Old, L. J.; Kassel, R. L.; Green, S.; Fiore, N.; Williamson, B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. U.S.A., 1975, 72, 3666-3670.
31. Furrer, M.; Altermatt, H. J.; Ris, H. B.; Althaus, U.; Ruegg, C.; Lienard, D.; Lejeune, F. J. Lack of antitumour activity of human recombinant tumour necrosis factor-alpha, alone or in combination with melphalan in a nude mouse human melanoma xenograft system. Melanoma Res., 1997, 7 Suppl 2, S43-S49.
32. Van de Wiel, P. A.; Bloksma, N.; Kuper, C. F.; Hofhuis, F. M.; Willers, J. M. Macroscopic and microscopic early effects of tumour necrosis factor on murine Meth A sarcoma, and relation to curative activity. J. Pathol., 1989, 157, 65-73.
33. Shimomura, K.; Manda, T.; Mukumoto, S.; Kobayashi, K.; Nakano, K.; Mori, J. Recombinant human tumor necrosis factor-alpha: thrombus formation is a cause of anti-tumor activity. Int. J. Cancer, 1988, 41, 243-247.
34. Balkwill, F. R.; Lee, A.; Aldam, G.; Moodie, E.; Thomas, J. A.; Tavernier, J.; Fiers, W. Human tumor xenografts treated with recombinant human tumor necrosis factor alone or in combination with interferons. Cancer Res., 1986, 46, 3990-3993.
35. Fajardo, L. F.; Kwan, H. H.; Kowalski, J.; Prionas, S. D.; Allison, A. C. Dual role of tumor necrosis factor-alpha in angiogenesis. Am. J. Pathol., 1992, 140, 539-544.
36. van Etten, B.; de Vries, M. R.; van, I. M. G.; Lans, T. E.; Guetens, G.; Ambagtsheer, G.; van Tiel, S. T.; de Boeck, G.; de Bruijn, E. A.; Eggermont, A. M.; ten Hagen, T. L. Degree of tumour vascularity correlates with drug accumulation and tumour response upon TNF-alpha-based isolated hepatic perfusion. Br. J. Cancer, 2003, 88, 314-319.
37. Huang, X.; Molema, G.; King, S.; Watkins, L.; Edgington, T. S.; Thorpe, P. E. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science, 1997, 275, 547-550.
38. Vandenabeele, P.; Declercq, W.; Vercammen, D.; Van de Craen, M.; Grooten, J.; Loetscher, H.; Brockhaus, M.; Lesslauer, W.; Fiers, W. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma. J. Exp. Med., 1992, 176, 1015-1024.
39. Stoelcker, B.; Ruhland, B.; Hehlgans, T.; Bluethmann, H.; Luther, T.; Mannel, D. N. Tumor necrosis factor induces tumor necrosis via tumor necrosis factor receptor type 1-expressing endothelial cells of the tumor vasculature. Am. J. Pathol., 2000, 156, 1171-1176.
40. Ruegg, C.; Yilmaz, A.; Bieler, G.; Bamat, J.; Chaubert, P.; Lejeune, F. J. Evidence for the involvement of endothelial cell integrin alphaVbeta3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma. Nat. Med., 1998, 4, 408-414.
41. Brooks, P. C.; Montgomery, A. M.; Rosenfeld, M.; Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 1994, 79, 1157-1164.
42. Mocellin, S.; Provenzano, M.; Rossi, C. R.; Pilati, P.; Scalerta, R.; Lise, M.; Nitti, D. Induction of endothelial nitric oxide synthase expression by melanoma sensitizes endothelial cells to tumor necrosis factor-driven cytotoxicity. Clin. Cancer Res., 2004, 10, 6879-6886.
43. Nooijen, P. T.; Manusama, E. R.; Eggermont, A. M.; Schalkwijk, L.; Stavast, J.; Marquet, R. L.; de Waal, R. M.; Ruiter, D. J. Synergistic effects of TNF-alpha and melphalan in an isolated limb perfusion model of rat sarcoma: a histopathological, immunohistochemical and electron microscopical study. Br. J. Cancer, 1996, 74, 1908-1915.
44. Manusama, E. R.; Nooijen, P. T.; Stavast, J.; Durante, N. M.; Marquet, R. L.; Eggermont, A. M. Synergistic antitumour effect of recombinant human tumour necrosis factor alpha with melphalan in isolated limb perfusion in the rat. Br. J. Surg., 1996, 83, 551-555.
45. Lejeune, F. J.; Ruegg, C.; Lienard, D. Clinical applications of TNFalpha in cancer. Curr. Opin. Immunol., 1998, 10, 573-580.
46. Hagen, T. L.; Eggermont, A. M. Tumor vascular therapy with TNF: critical review on animal models. Methods Mol. Med., 2004, 98, 227-246.
47. van Horssen, R.; Ten Hagen, T. L.; Eggermont, A. M. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist, 2006, 11, 397-408.
48. Lejeune, F. J. Clinical use of TNF revisited: improving penetration of anti-cancer agents by increasing vascular permeability. J. Clin. Invest., 2002, 110, 433-435.
49. LeBlanc, H.; Lawrence, D.; Varfolomeev, E.; Totpal, K.; Morlan, J.; Schow, P.; Fong, S.; Schwall, R.; Sinicropi, D.; Ashkenazi, A. Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax. Nat. Med., 2002, 8, 274-281.
50. Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer, 2009, 9, 361-371.
51. Mocellin, S.; Rossi, C. R.; Pilati, P.; Nitti, D. Tumor necrosis factor, cancer and anticancer therapy. Cytokine Growth Factor Rev., 2005, 16, 35-53.
52. Wu, S.; Boyer, C. M.; Whitaker, R. S.; Berchuck, A.; Wiener, J. R.; Weinberg, J. B.; Bast, R. C., Jr. Tumor necrosis factor alpha as an autocrine and paracrine growth factor for ovarian cancer: monokine induction of tumor cell proliferation and tumor necrosis factor alpha expression. Cancer Res., 1993, 53, 1939-1944.
53. Tselepis, C.; Perry, I.; Dawson, C.; Hardy, R.; Darnton, S. J.; McConkey, C.; Stuart, R. C.; Wright, N.; Harrison, R.; Jankowski, J. A. Tumour necrosis factor-alpha in Barrett's oesophagus: a potential novel mechanism of action. Oncogene, 2002, 21, 6071-6081.
54. Humblet, C.; Greimers, R.; Delvenne, P.; Deman, J.; Boniver, J.; Defresne, M. P. Prevention of murine radiogenic thymic lymphomas by tumor necrosis factor or by marrow grafting. J. Natl. Cancer Inst., 1996, 88, 824-831.
55. Moore, R. J.; Owens, D. M.; Stamp, G.; Arnott, C.; Burke, F.; East, N.; Holdsworth, H.; Turner, L.; Rollins, B.; Pasparakis, M.; Kollias, G.; Balkwill, F. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat. Med., 1999, 5, 828-831.
56. Jaiswal, M.; LaRusso, N. F.; Burgart, L. J.; Gores, G. J. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res., 2000, 60, 184-190.
57. Arnott, C. H.; Scott, K. A.; Moore, R. J.; Hewer, A.; Phillips, D. H.; Parker, P.; Balkwill, F. R.; Owens, D. M. Tumour necrosis factor-alpha mediates tumour promotion via a PKC alpha- and AP-1- dependent pathway. Oncogene, 2002, 21, 4728-4738.
58. Orosz, P.; Echtenacher, B.; Falk, W.; Ruschoff, J.; Weber, D.; Mannel, D. N. Enhancement of experimental metastasis by tumor necrosis factor. J. Exp. Med., 1993, 177, 1391-1398.
59. Waterston, A. M.; Salway, F.; Andreakos, E.; Butler, D. M.; Feldmann, M.; Coombes, R. C. TNF autovaccination induces self anti- TNF antibodies and inhibits metastasis in a murine melanoma model. Br. J. Cancer, 2004, 90, 1279-1284.
60. Kitakata, H.; Nemoto-Sasaki, Y.; Takahashi, Y.; Kondo, T.; Mai, M.; Mukaida, N. Essential roles of tumor necrosis factor receptor p55 in liver metastasis of intrasplenic administration of colon 26 cells. Cancer Res., 2002, 62, 6682-6687.
61. Qin, Z.; Kruger-Krasagakes, S.; Kunzendorf, U.; Hock, H.; Diamantstein, T.; Blankenstein, T. Expression of tumor necrosis factor by different tumor cell lines results either in tumor suppression or augmented metastasis. J. Exp. Med., 1993, 178, 355-360.
62. Wolfe, F.; Michaud, K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum., 2007, 56, 2886-2895.
63. Bongartz, T.; Sutton, A. J.; Sweeting, M. J.; Buchan, I.; Matteson, E. L.; Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA, 2006, 295, 2275-2285.
64. Bongartz, T.; Warren, F. C.; Mines, D.; Matteson, E. L.; Abrams, K. R.; Sutton, A. J. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. Ann. Rheum. Dis., 2009, 68, 1177-1183.
65. Anderson, G. M.; Nakada, M. T.; DeWitte, M. Tumor necrosis factor-alpha in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol., 2004, 4, 314-320.
66. Verhoef, C.; de Wilt, J. H.; Grunhagen, D. J.; van Geel, A. N.; ten Hagen, T. L.; Eggermont, A. M. Isolated limb perfusion with melphalan and TNF-alpha in the treatment of extremity sarcoma. Curr. Treat. Options Oncol., 2007, 8, 417-427.
67. Eggermont, A. M.; de Wilt, J. H.; ten Hagen, T. L. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol., 2003, 4, 429-437.
68. Bellavance, E. C.; Alexander, H. R., Jr. TNF-based isolated hepatic perfusion. Front. Biosci., 2009, 14, 1771-1784.
69. Rossi, C. R.; Foletto, M.; Pilati, P.; Mocellin, S.; Lise, M. Isolated limb perfusion in locally advanced cutaneous melanoma. Semin. Oncol., 2002, 29, 400-409.
70. Rossi, C. R.; Mocellin, S.; Pilati, P.; Foletto, M.; Nitti, D.; Lise, M. TNFalpha-based isolated perfusion for limb-threatening soft tissue sarcomas: state of the art and future trends. J. Immunother., 2003, 26, 291-300.
71. Weichselbaum, R. R.; Kufe, D. W.; Hellman, S.; Rasmussen, H. S.; King, C. R.; Fischer, P. H.; Mauceri, H. J. Radiation-induced tumour necrosis factor-alpha expression: clinical application of transcriptional and physical targeting of gene therapy. Lancet Oncol., 2002, 3, 665-671.
72. Senzer, N.; Mani, S.; Rosemurgy, A.; Nemunaitis, J.; Cunningham, C.; Guha, C.; Bayol, N.; Gillen, M.; Chu, K.; Rasmussen, C.; Rasmussen, H.; Kufe, D.; Weichselbaum, R.; Hanna, N. TNFerade biologic, an adenovector with a radiation-inducible promoter, carrying the human tumor necrosis factor alpha gene: a phase I study in patients with solid tumors. J. Clin. Oncol., 2004, 22, 592-601.
73. McLoughlin, J. M.; McCarty, T. M.; Cunningham, C.; Clark, V.; Senzer, N.; Nemunaitis, J.; Kuhn, J. A. TNFerade, an adenovector carrying the transgene for human tumor necrosis factor alpha, for patients with advanced solid tumors: surgical experience and longterm follow-up. Ann. Surg. Oncol., 2005, 12, 825-830.
74. Mundt, A. J.; Vijayakumar, S.; Nemunaitis, J.; Sandler, A.; Schwartz, H.; Hanna, N.; Peabody, T.; Senzer, N.; Chu, K.; Rasmussen, C. S.; Kessler, P. D.; Rasmussen, H. S.; Warso, M.; Kufe, D. W.; Gupta, T. D.; Weichselbaum, R. R. A Phase I trial of TNFerade biologic in patients with soft tissue sarcoma in the extremities. Clin. Cancer Res., 2004, 10, 5747-5753.
75. MacGill, R. S.; Davis, T. A.; Macko, J.; Mauceri, H. J.; Weichselbaum, R. R.; King, C. R. Local gene delivery of tumor necrosis factor alpha can impact primary tumor growth and metastases through a host-mediated response. Clin. Exp. Metastasis, 2007, 24, 521-531.
76. Chaudhari, B. R.; Murphy, R. F.; Agrawal, D. K. Following the TRAIL to apoptosis. Immunol. Res., 2006, 35, 249-262.
77. Schaefer, U.; Voloshanenko, O.; Willen, D.; Walczak, H. TRAIL: a multifunctional cytokine. Front. Biosci., 2007, 12, 3813-3824.
78. Jo, M.; Kim, T. H.; Seol, D. W.; Esplen, J. E.; Dorko, K.; Billiar, T. R.; Strom, S. C. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med., 2000, 6, 564-567.
79. Lawrence, D.; Shahrokh, Z.; Marsters, S.; Achilles, K.; Shih, D.; Mounho, B.; Hillan, K.; Totpal, K.; DeForge, L.; Schow, P.; Hooley, J.; Sherwood, S.; Pai, R.; Leung, S.; Khan, L.; Gliniak, B.; Bussiere, J.; Smith, C. A.; Strom, S. S.; Kelley, S.; Fox, J. A.; Thomas, D.; Ashkenazi, A. Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions. Nat. Med., 2001, 7, 383-385.
80. Pennarun, B.; Meijer, A.; de Vries, E. G.; Kleibeuker, J. H.; Kruyt, F.; de Jong, S. Playing the DISC: Turning on TRAIL death receptor- mediated apoptosis in cancer. Biochim. Biophys. Acta, 2009.
81. Holoch, P. A.; Griffith, T. S. TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies. Eur. J. Pharmacol., 2009, 625, 63-72.
82. Cretney, E.; Takeda, K.; Yagita, H.; Glaccum, M.; Peschon, J. J.; Smyth, M. J. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J. Immunol., 2002, 168, 1356-1361.
83. Finnberg, N.; El-Deiry, W. S. TRAIL death receptors as tumor suppressors and drug targets. Cell Cycle, 2008, 7, 1525-1528.
84. Humphreys, R. C.; Halpern, W. Trail receptors: targets for cancer therapy. Adv. Exp. Med. Biol., 2008, 615, 127-158.
85. Walczak, H.; Haas, T. L. Biochemical analysis of the native TRAIL death-inducing signaling complex. Methods Mol. Biol., 2008, 414, 221-239.
86. Barnhart, B. C.; Alappat, E. C.; Peter, M. E. The CD95 type I/type II model. Semin. Immunol., 2003, 15, 185-193.
87. Ledgerwood, E. C.; Morison, I. M. Targeting the apoptosome for cancer therapy. Clin Cancer Res., 2009, 15, 420-424.
88. D'Amelio, M.; Tino, E.; Cecconi, F. The apoptosome: emerging insights and new potential targets for drug design. Pharm. Res., 2008, 25, 740-751.
89. Dyer, M. J.; MacFarlane, M.; Cohen, G. M. Barriers to effective TRAIL-targeted therapy of malignancy. J. Clin. Oncol., 2007, 25, 4505-4506.
90. Sheridan, J. P.; Marsters, S. A.; Pitti, R. M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C. L.; Baker, K.; Wood, W. I.; Goddard, A. D.; Godowski, P.; Ashkenazi, A. Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors. Science, 1997, 277, 818-821.
91. Sheikh, M. S.; Huang, Y.; Fernandez-Salas, E. A.; El-Deiry, W. S.; Friess, H.; Amundson, S.; Yin, J.; Meltzer, S. J.; Holbrook, N. J.; Fornace, A. J., Jr. The antiapoptotic decoy receptor TRID/TRAILR3 is a p53-regulated DNA damage-inducible gene that is overexpressed in primary tumors of the gastrointestinal tract. Oncogene, 1999, 18, 4153-4159.
92. Sanlioglu, A. D.; Karacay, B.; Koksal, I. T.; Griffith, T. S.; Sanlioglu, S. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther., 2007, 14, 976-984.
93. Buneker, C.; Mohr, A.; Zwacka, R. M. The TRAIL-receptor-1: TRAIL-receptor-3 and -4 ratio is a predictor for TRAIL sensitivity of cancer cells. Oncol. Rep., 2009, 21, 1289-1295.
94. Spierings, D. C.; de Vries, E. G.; Vellenga, E.; van den Heuvel, F. A.; Koornstra, J. J.; Wesseling, J.; Hollema, H.; de Jong, S. Tissue distribution of the death ligand TRAIL and its receptors. J. Histochem. Cytochem., 2004, 52, 821-831.
95. Pineau, P.; Nagai, H.; Prigent, S.; Wei, Y.; Gyapay, G.; Weissenbach, J.; Tiollais, P.; Buendia, M. A.; Dejean, A. Identification of three distinct regions of allelic deletions on the short arm of chromosome 8 in hepatocellular carcinoma. Oncogene, 1999, 18, 3127-3134.
96. Arai, T.; Akiyama, Y.; Okabe, S.; Saito, K.; Iwai, T.; Yuasa, Y. Genomic organization and mutation analyses of the DR5/TRAIL receptor 2 gene in colorectal carcinomas. Cancer Lett., 1998, 133, 197-204.
97. Jeng, Y. M.; Hsu, H. C. Mutation of the DR5/TRAIL receptor 2 gene is infrequent in hepatocellular carcinoma. Cancer Lett., 2002, 181, 205-208.
98. Park, W. S.; Lee, J. H.; Shin, M. S.; Park, J. Y.; Kim, H. S.; Kim, Y. S.; Park, C. H.; Lee, S. K.; Lee, S. H.; Lee, S. N.; Kim, H.; Yoo, N. J.; Lee, J. Y. Inactivating mutations of KILLER/DR5 gene in gastric cancers. Gastroenterology, 2001, 121, 1219-1225.
99. Shin, M. S.; Kim, H. S.; Lee, S. H.; Park, W. S.; Kim, S. Y.; Park, J. Y.; Lee, J. H.; Lee, S. K.; Lee, S. N.; Jung, S. S.; Han, J. Y.; Kim, H.; Lee, J. Y.; Yoo, N. J. Mutations of tumor necrosis factorrelated apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer Res., 2001, 61, 4942-4946.
100. Jin, Z.; Dicker, D. T.; El-Deiry, W. S. Enhanced sensitivity of G1 arrested human cancer cells suggests a novel therapeutic strategy using a combination of simvastatin and TRAIL. Cell Cycle, 2002, 1, 82-89.
101. Algeciras-Schimnich, A.; Griffith, T. S.; Lynch, D. H.; Paya, C. V. Cell cycle-dependent regulation of FLIP levels and susceptibility to Fas-mediated apoptosis. J. Immunol., 1999, 162, 5205-5211.
102. Fulda, S.; Meyer, E.; Debatin, K. M. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene, 2002, 21, 2283-2294.
103. Fulda, S.; Wick, W.; Weller, M.; Debatin, K. M. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med., 2002, 8, 808-815.
104. Griffith, T. S.; Fialkov, J. M.; Scott, D. L.; Azuhata, T.; Williams, R. D.; Wall, N. R.; Altieri, D. C.; Sandler, A. D. Induction and regulation of tumor necrosis factor-related apoptosis-inducing ligand/Apo-2 ligand-mediated apoptosis in renal cell carcinoma. Cancer Res., 2002, 62, 3093-3099.
105. Plastaras, J. P.; Dorsey, J. F.; Carroll, K.; Kim, S. H.; Birnbaum, M. J.; El-Deiry, W. S. Role of PI3K/Akt signaling in TRAIL- and radiation-induced gastrointestinal apoptosis. Cancer Biol. Ther., 2008, 7, 2047-2053.
106. Kim, S. H.; Ricci, M. S.; El-Deiry, W. S. Mcl-1: a gateway to TRAIL sensitization. Cancer Res., 2008, 68, 2062-2064.
107. Nesterov, A.; Lu, X.; Johnson, M.; Miller, G. J.; Ivashchenko, Y.; Kraft, A. S. Elevated AKT activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis. J. Biol. Chem., 2001, 276, 10767-10774.
108. Vaculova, A.; Hofmanova, J.; Soucek, K.; Kozubik, A. Different modulation of TRAIL-induced apoptosis by inhibition of prosurvival pathways in TRAIL-sensitive and TRAIL-resistant colon cancer cells. FEBS Lett., 2006, 580, 6565-6569.
109. Geserick, P.; Drewniok, C.; Hupe, M.; Haas, T. L.; Diessenbacher, P.; Sprick, M. R.; Schon, M. P.; Henkler, F.; Gollnick, H.; Walczak, H.; Leverkus, M. Suppression of cFLIP is sufficient to sensitize human melanoma cells to TRAIL- and CD95L-mediated apoptosis. Oncogene, 2008, 27, 3211-3220.
110. Siegmund, D.; Hadwiger, P.; Pfizenmaier, K.; Vornlocher, H. P.; Wajant, H. Selective inhibition of FLICE-like inhibitory protein expression with small interfering RNA oligonucleotides is sufficient to sensitize tumor cells for TRAIL-induced apoptosis. Mol. Med., 2002, 8, 725-732.
111. Schimmer, A. D.; Welsh, K.; Pinilla, C.; Wang, Z.; Krajewska, M.; Bonneau, M. J.; Pedersen, I. M.; Kitada, S.; Scott, F. L.; Bailly-Maitre, B.; Glinsky, G.; Scudiero, D.; Sausville, E.; Salvesen, G.; Nefzi, A.; Ostresh, J. M.; Houghten, R. A.; Reed, J. C. Smallmolecule antagonists of apoptosis suppressor XIAP exhibit broad antitumor activity. Cancer Cell, 2004, 5, 25-35.
112. Sinicrope, F. A.; Penington, R. C.; Tang, X. M. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res., 2004, 10, 8284-8292.
113. Clohessy, J. G.; Zhuang, J.; de Boer, J.; Gil-Gomez, G.; Brady, H. J. Mcl-1 interacts with truncated Bid and inhibits its induction of cytochrome c release and its role in receptor-mediated apoptosis. J. Biol. Chem., 2006, 281, 5750-5759.
114. Ndozangue-Touriguine, O.; Sebbagh, M.; Merino, D.; Micheau, O.; Bertoglio, J.; Breard, J. A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. Oncogene, 2008, 27, 6012-6022.
115. Wiley, S. R.; Schooley, K.; Smolak, P. J.; Din, W. S.; Huang, C. P.; Nicholl, J. K.; Sutherland, G. R.; Smith, T. D.; Rauch, C.; Smith, C. A.; et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity, 1995, 3, 673-682.
116. Ashkenazi, A.; Pai, R. C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; McMurtrey, A. E.; Hebert, A.; DeForge, L.; Koumenis, I. L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R. H. Safety and antitumor activity of recombinant soluble Apo2 ligand. J. Clin. Invest., 1999, 104, 155-162.
117. Wu, G. S. TRAIL as a target in anti-cancer therapy. Cancer Lett., 2009, 285, 1-5.
118. Kelley, S. K.; Harris, L. A.; Xie, D.; Deforge, L.; Totpal, K.; Bussiere, J.; Fox, J. A. Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: characterization of in vivo efficacy, pharmacokinetics, and safety. J. Pharmacol. Exp. Ther., 2001, 299, 31-38.
119. Marini, P.; Schmid, A.; Jendrossek, V.; Faltin, H.; Daniel, P. T.; Budach, W.; Belka, C. Irradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosis. BMC Cancer, 2005, 5, 5.
120. Stieglmaier, J.; Bremer, E.; Kellner, C.; Liebig, T. M.; ten Cate, B.; Peipp, M.; Schulze-Koops, H.; Pfeiffer, M.; Buhring, H. J.; Greil, J.; Oduncu, F.; Emmerich, B.; Fey, G. H.; Helfrich, W. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19- specific TRAIL fusion protein. Cancer Immunol. Immunother., 2008, 57, 233-246.
121. Frese, S.; Schuller, A.; Frese-Schaper, M.; Gugger, M.; Schmid, R. A. Cytotoxic effects of camptothecin and cisplatin combined with tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) in a model of primary culture of non-small cell lung cancer. Anticancer Res., 2009, 29, 2905-2911.
122. Yeh, C. C.; Deng, Y. T.; Sha, D. Y.; Hsiao, M.; Kuo, M. Y. Suberoylanilide hydroxamic acid sensitizes human oral cancer cells to TRAIL-induced apoptosis through increase DR5 expression. Mol. Cancer Ther., 2009, 8, 2718-2725.
123. Chinnaiyan, A. M.; Prasad, U.; Shankar, S.; Hamstra, D. A.; Shanaiah, M.; Chenevert, T. L.; Ross, B. D.; Rehemtulla, A. Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. Proc. Natl. Acad. Sci. U S A, 2000, 97, 1754-1759.
124. Liu, X.; Yue, P.; Khuri, F. R.; Sun, S. Y. p53 upregulates death receptor 4 expression through an intronic p53 binding site. Cancer Res., 2004, 64, 5078-5083.
125. Shankar, S.; Srivastava, R. K. Enhancement of therapeutic potential of TRAIL by cancer chemotherapy and irradiation: mechanisms and clinical implications. Drug Resist. Updat., 2004, 7, 139-156.
126. Bonvini, P.; Zorzi, E.; Basso, G.; Rosolen, A. Bortezomibmediated 26S proteasome inhibition causes cell-cycle arrest and induces apoptosis in CD-30+ anaplastic large cell lymphoma. Leukemia, 2007, 21, 838-842.
127. Sayers, T. J.; Brooks, A. D.; Koh, C. Y.; Ma, W.; Seki, N.; Raziuddin, A.; Blazar, B. R.; Zhang, X.; Elliott, P. J.; Murphy, W. J. The proteasome inhibitor PS-341 sensitizes neoplastic cells to TRAIL mediated apoptosis by reducing levels of c-FLIP. Blood, 2003, 102, 303-310.
128. Brooks, A. D.; Ramirez, T.; Toh, U.; Onksen, J.; Elliott, P. J.; Murphy, W. J.; Sayers, T. J. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAILmediated apoptosis. Ann. N. Y. Acad. Sci., 2005, 1059, 160-167.
129. Luster, T. A.; Carrell, J. A.; McCormick, K.; Sun, D.; Humphreys, R. Mapatumumab and lexatumumab induce apoptosis in TRAILR1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib. Mol. Cancer Ther., 2009, 8, 292-302.
130. Rosato, R. R.; Almenara, J. A.; Coe, S.; Grant, S. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res., 2007, 67, 9490-9500.
131. Borbone, E.; Berlingieri, M. T.; De Bellis, F.; Nebbioso, A.; Chiappetta, G.; Mai, A.; Altucci, L.; Fusco, A. Histone deacetylase inhibitors induce thyroid cancer-specific apoptosis through proteasome- dependent inhibition of TRAIL degradation. Oncogene, 2010, 29, 105-116.
132. Carew, J. S.; Giles, F. J.; Nawrocki, S. T. Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett., 2008, 269, 7-17.
133. Fulda, S. Modulation of TRAIL-induced apoptosis by HDAC inhibitors. Curr. Cancer Drug Targets, 2008, 8, 132-140.
134. Ray, S.; Bucur, O.; Almasan, A. Sensitization of prostate carcinoma cells to Apo2L/TRAIL by a Bcl-2 family protein inhibitor. Apoptosis, 2005, 10, 1411-1418.
135. Zhu, H.; Guo, W.; Zhang, L.; Davis, J. J.; Wu, S.; Teraishi, F.; Cao, X.; Smythe, W. R.; Fang, B. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol. Ther., 2005, 4, 393-397.
136. Petrucci, E.; Pasquini, L.; Petronelli, A.; Saulle, E.; Mariani, G.; Riccioni, R.; Biffoni, M.; Ferretti, G.; Benedetti-Panici, P.; Cognetti, F.; Scambia, G.; Humphreys, R.; Peschle, C.; Testa, U. A small molecule Smac mimic potentiates TRAIL-mediated cell death of ovarian cancer cells. Gynecol. Oncol., 2007, 105, 481-492.
137. Vogler, M.; Walczak, H.; Stadel, D.; Haas, T. L.; Genze, F.; Jovanovic, M.; Bhanot, U.; Hasel, C.; Moller, P.; Gschwend, J. E.; Simmet, T.; Debatin, K. M.; Fulda, S. Small molecule XIAP inhibitors enhance TRAIL-induced apoptosis and antitumor activity in preclinical models of pancreatic carcinoma. Cancer Res., 2009, 69, 2425-2434.
138. Griffith, T. S.; Anderson, R. D.; Davidson, B. L.; Williams, R. D.; Ratliff, T. L. Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J. Immunol., 2000, 165, 2886-2894.
139. Griffith, T. S.; Broghammer, E. L. Suppression of tumor growth following intralesional therapy with TRAIL recombinant adenovirus. Mol. Ther., 2001, 4, 257-266.
140. Ashkenazi, A.; Holland, P.; Eckhardt, S. G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol., 2008, 26, 3621-3630.
141. Armeanu, S.; Lauer, U. M.; Smirnow, I.; Schenk, M.; Weiss, T. S.; Gregor, M.; Bitzer, M. Adenoviral gene transfer of tumor necrosis factor-related apoptosis-inducing ligand overcomes an impaired response of hepatoma cells but causes severe apoptosis in primary human hepatocytes. Cancer Res., 2003, 63, 2369-2372.
142. Dong, F.; Wang, L.; Davis, J. J.; Hu, W.; Zhang, L.; Guo, W.; Teraishi, F.; Ji, L.; Fang, B. Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosisinducing ligand-armed oncolytic adenovirus. Clin. Cancer Res., 2006, 12, 5224-5230.
143. Kock, N.; Kasmieh, R.; Weissleder, R.; Shah, K. Tumor therapy mediated by lentiviral expression of shBcl-2 and S-TRAIL. Neoplasia, 2007, 9, 435-442.
144. Lillehammer, T.; Engesaeter, B. O.; Prasmickaite, L.; Maelandsmo, G. M.; Fodstad, O.; Engebraaten, O. Combined treatment with AdhTRAIL and DTIC or SAHA is associated with increased mitochondrial- mediated apoptosis in human melanoma cell lines. J. Gene Med., 2007, 9, 440-451.
145. Wenger, T.; Mattern, J.; Haas, T. L.; Sprick, M. R.; Walczak, H.; Debatin, K. M.; Buchler, M. W.; Herr, I. Apoptosis mediated by lentiviral TRAIL transfer involves transduction-dependent and - independent effects. Cancer Gene Ther., 2007, 14, 316-326.
146. Bremer, E.; van Dam, G. M.; de Bruyn, M.; van Riezen, M.; Dijkstra, M.; Kamps, G.; Helfrich, W.; Haisma, H. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol. Ther., 2008, 16, 1919-1926.
147. Ashkenazi, A. Directing cancer cells to self-destruct with proapoptotic receptor agonists. Nat. Rev. Drug Discov., 2008, 7, 1001-1012.
148. Bellail, A. C.; Qi, L.; Mulligan, P.; Chhabra, V.; Hao, C. TRAIL agonists on clinical trials for cancer therapy: the promises and the challenges. Rev. Recent Clin. Trials, 2009, 4, 34-41.
149. Tolcher, A. W.; Mita, M.; Meropol, N. J.; von Mehren, M.; Patnaik, A.; Padavic, K.; Hill, M.; Mays, T.; McCoy, T.; Fox, N. L.; Halpern, W.; Corey, A.; Cohen, R. B. Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factorrelated apoptosis-inducing ligand receptor-1. J. Clin. Oncol., 2007, 25, 1390-1395.
150. Trarbach, T.; Moehler, M.; Heinemann, V.; Kohne, C. H.; Przyborek, M.; Schulz, C.; Sneller, V.; Gallant, G.; Kanzler, S. Phase IItrial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis- inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer. Br. J. Cancer, 2010, 102, 506-512.
151. Greco, F. A.; Bonomi, P.; Crawford, J.; Kelly, K.; Oh, Y.; Halpern, W.; Lo, L.; Gallant, G.; Klein, J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer, 2008, 61, 82-90.
152. Mom, C. H.; Verweij, J.; Oldenhuis, C. N.; Gietema, J. A.; Fox, N. L.; Miceli, R.; Eskens, F. A.; Loos, W. J.; de Vries, E. G.; Sleijfer, S. Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study. Clin. Cancer Res., 2009, 15, 5584-5590.
153. Plummer, R.; Attard, G.; Pacey, S.; Li, L.; Razak, A.; Perrett, R.; Barrett, M.; Judson, I.; Kaye, S.; Fox, N. L.; Halpern, W.; Corey, A.; Calvert, H.; de Bono, J. Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers. Clin. Cancer Res., 2007, 13, 6187-6194.
154. Adams, C.; Totpal, K.; Lawrence, D.; Marsters, S.; Pitti, R.; Yee, S.; Ross, S.; Deforge, L.; Koeppen, H.; Sagolla, M.; Compaan, D.; Lowman, H.; Hymowitz, S.; Ashkenazi, A. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. Cell Death Differ., 2008, 15, 751-761.
155. Camidge, D. R. Apomab: an agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert Opin. Biol. Ther., 2008, 8, 1167-1176.
156. Strasser, A.; Jost, P. J.; Nagata, S. The many roles of FAS receptor signaling in the immune system. Immunity, 2009, 30, 180-192.
157. Lavrik, I. N.; Mock, T.; Golks, A.; Hoffmann, J. C.; Baumann, S.; Krammer, P. H. CD95 stimulation results in the formation of a novel death effector domain protein-containing complex. J. Biol. Chem., 2008, 283, 26401-26408.
158. Houston, A.; O'Connell, J. The Fas signalling pathway and its role in the pathogenesis of cancer. Curr. Opin. Pharmacol., 2004, 4, 321-326.
159. Curtin, J. F.; Cotter, T. G. Live and let die: regulatory mechanisms in Fas-mediated apoptosis. Cell Signal, 2003, 15, 983-992.
160. Lavrik, I.; Golks, A.; Krammer, P. H. Death receptor signaling. J. Cell Sci., 2005, 118, 265-267.
161. Chang, D. W.; Xing, Z.; Capacio, V. L.; Peter, M. E.; Yang, X. Interdimer processing mechanism of procaspase-8 activation. EMBO J., 2003, 22, 4132-4142.
162. Thome, M.; Schneider, P.; Hofmann, K.; Fickenscher, H.; Meinl, E.; Neipel, F.; Mattmann, C.; Burns, K.; Bodmer, J. L.; Schroter, M.; Scaffidi, C.; Krammer, P. H.; Peter, M. E.; Tschopp, J. Viral FLICE-inhibitory proteins (FLIPs) prevent apoptosis induced by death receptors. Nature, 1997, 386, 517-521.
163. Scaffidi, C.; Fulda, S.; Srinivasan, A.; Friesen, C.; Li, F.; Tomaselli, K. J.; Debatin, K. M.; Krammer, P. H.; Peter, M. E. Two CD95 (APO-1/Fas) signaling pathways. EMBO J., 1998, 17, 1675-1687.
164. Willis, S.; Day, C. L.; Hinds, M. G.; Huang, D. C. The Bcl-2- regulated apoptotic pathway. J Cell Sci., 2003, 116, 4053-4056.
165. Trauth, B. C.; Klas, C.; Peters, A. M.; Matzku, S.; Moller, P.; Falk, W.; Debatin, K. M.; Krammer, P. H. Monoclonal antibodymediated tumor regression by induction of apoptosis. Science, 1989, 245, 301-305.
166. O'Brien, D. I.; Nally, K.; Kelly, R. G.; O'Connor, T. M.; Shanahan, F.; O'Connell, J. Targeting the Fas/Fas ligand pathway in cancer. Expert Opin. Ther. Targets, 2005, 9, 1031-1044.
167. Linkermann, A.; Qian, J.; Lettau, M.; Kabelitz, D.; Janssen, O. Considering Fas ligand as a target for therapy. Expert Opin. Ther. Targets, 2005, 9, 119-134.
168. Houghton, J. A.; Harwood, F. G.; Tillman, D. M. Thymineless death in colon carcinoma cells is mediated via fas signaling. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 8144-8149.
169. Kasibhatla, S.; Brunner, T.; Genestier, L.; Echeverri, F.; Mahboubi, A.; Green, D. R. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol. Cell, 1998, 1, 543-551.
170. Muller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedman, S. L.; Galle, P. R.; Stremmel, W.; Oren, M.; Krammer, P. H. p53 activates the CD95 (APO-1/Fas) gene in response to DNA damage by anticancer drugs. J. Exp. Med., 1998, 188, 2033-2045.
171. Micheau, O.; Hammann, A.; Solary, E.; Dimanche-Boitrel, M. T. STAT-1-independent upregulation of FADD and procaspase-3 and -8 in cancer cells treated with cytotoxic drugs. Biochem. Biophys. Res. Commun., 1999, 256, 603-607.
172. Fulda, S.; Meyer, E.; Friesen, C.; Susin, S. A.; Kroemer, G.; Debatin, K. M. Cell type specific involvement of death receptor and mitochondrial pathways in drug-induced apoptosis. Oncogene, 2001, 20, 1063-1075.
173. Timmer, T.; de Vries, E. G.; de Jong, S. Fas receptor-mediated apoptosis: a clinical application? J. Pathol., 2002, 196, 125-134.
174. Papenfuss, K.; Cordier, S. M.; Walczak, H. Death receptors as targets for anti-cancer therapy. J. Cell Mol. Med., 2008, 12, 2566-2585.
175. Arai, H.; Gordon, D.; Nabel, E. G.; Nabel, G. J. Gene transfer of Fas ligand induces tumor regression in vivo. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 13862-13867.
176. Aoki, K.; Kurooka, M.; Chen, J. J.; Petryniak, J.; Nabel, E. G.; Nabel, G. J. Extracellular matrix interacts with soluble CD95L: retention and enhancement of cytotoxicity. Nat. Immunol., 2001, 2, 333-337.
177. Samel, D.; Muller, D.; Gerspach, J.; Assohou-Luty, C.; Sass, G.; Tiegs, G.; Pfizenmaier, K.; Wajant, H. Generation of a FasL-basedproapoptotic fusion protein devoid of systemic toxicity due to cell surface antigen-restricted Activation. J. Biol. Chem., 2003, 278, 32077-32082.
178. Nishimura, Y.; Hirabayashi, Y.; Matsuzaki, Y.; Musette, P.; Ishii, A.; Nakauchi, H.; Inoue, T.; Yonehara, S. In vivo analysis of Fas antigen-mediated apoptosis: effects of agonistic anti-mouse Fas mAb on thymus, spleen and liver. Int. Immunol., 1997, 9, 307-316.
179. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal effect of the anti-Fas antibody in mice. Nature, 1993, 364, 806-809.
180. Nishimura-Morita, Y.; Nose, M.; Inoue, T.; Yonehara, S. Amelioration of systemic autoimmune disease by the stimulation of apoptosis- promoting receptor Fas with anti-Fas mAb. Int. Immunol., 1997, 9, 1793-1799.
181. Ichikawa, K.; Yoshida-Kato, H.; Ohtsuki, M.; Ohsumi, J.; Yamaguchi, J.; Takahashi, S.; Tani, Y.; Watanabe, M.; Shiraishi, A.; Nishioka, K.; Yonehara, S.; Serizawa, N. A novel murine anti-human Fas mAb which mitigates lymphadenopathy without hepatotoxicity. Int. Immunol., 2000, 12, 555-562.
182. Gerspach, J.; Pfizenmaier, K.; Wajant, H. Improving TNF as a cancer therapeutic: tailor-made TNF fusion proteins with conserved antitumor activity and reduced systemic side effects. Biofactors, 2009, 35, 364-372.